Morris, Mark - University of Wolverhampton - Faculty of Science & Engineering

个人简介

Dr Mark Morris leads a research group within the Research Institute In Healthcare Science (RHIS) investigating the molecular biology and genetics of cancer development. Mark gained his PhD in 2001 following a period of research (at the University of Wales College of Medicine) into the regulation of proliferative life-span barriers in human tumours. Prior to joining the University of Wolverhampton, in 2010, Mark investigated the molecular basis of cancer and developmental diseases with a particulate interest in epigenetic gene dysregulation as a mechanism that drives tumour formation. This research was carried out at the Department of Medical Genetics, University of Birmingham, where he currently holds the post of Honorary Lecturer in Molecular Oncology. His teaching includes general biochemistry, cell biology, and molecular genetics, particularly related to human disease.

研究领域

The role of epigenetic gene dysregulation in the process of tumour formation and metastasis. The role epigenetics (in particular DNA methylation and microRNAs) play in the development of childhood cancers of the brain and the kidney. RNA-processing in tumour development. The identification of new therapeutics against cancer.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Morris MR* and Astuti D*, Cooper WN, Staals RHJ, Gentle D, Shuib S, Ricketts CR, Cole T, van Essen EJ, van Lingen R, Neri G, Opitz JM, Rump P, Stolte-Dijkstra I, Pruijn GJM, Latif F, Maher ER (2012). Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility. Nat Genet. 44: 277-84 Wake NC, Ricketts CJ, Morris MR, Prigmore E, Gribble SM, Skytte A, Brown M, Clarke N, Banks RE, Hodgson S, Turnell AS, Maher ER, Woodward ER (2013). UBE2QL1 is disrupted by a constitutional translocation associated with renal tumor predisposition and is a novel candidate renal tumor suppressor gene. Human Mutation doi: 10.1002/humu.22433 Ricketts CJ* and Morris MR*, Gentle D, Shuib S, Brown M, Clarke N, Wei W, Nathan P, Latif F, Maher ER (2013). Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma. Clinical Epigenetics 5: 16. Morris MR, Astuti D, Maher ER (2013). Perlman syndrome: overgrowth, Wilms tumor predisposition and DIS3L2. Am. J. Med. Genet. C Semin. Med. Genet. 9999:1–8. Shinawi T, Hill VK, Krex D, Schackert G, Gentle D, Morris MR, Wei W, Cruickshank G, Maher ER, Latif F (2013). DNA methylation profiles of long- and short-term glioblastoma survivors. Epigenetics 8: 149-156 Ricketts CJ, Morris MR, Gentle D, Brown M, Wake N, Woodward ER, Clarke N, Latif F, Maher ER (2012). Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics. 7: 278-90 Morris MR, Ricketts C, Gentle D, McRonald FE, Carli N, Khalili H, Brown M, Kishida T, Yao M, Banks RE, Clarke N, Latif F, Maher ER (2011). Genome-wide methylation analysis identifies epigenetically inactivated tumour suppressor genes in renal cell carcinoma.Oncogene 30:1390-401 Hill VK, Underhill-Day N, Krex D, Robel K, Sangan CB, Summersgill HR, Morris MR, Gentle D, Chalmers AD, Maher ER, Latif F (2011).Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene30:978-89 Morris MR and Maher ER (2010). Epigenetics of renal cancer: the path towards new diagnostics and therapeutics. Genome Medicine2:59 Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Latif F, Maher ER (2010). Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 29:2104-17